Last reviewed · How we verify
OTX-TKI
OTX-TKI is a tyrosine kinase inhibitor designed for topical ocular delivery to treat eye surface diseases.
OTX-TKI is a tyrosine kinase inhibitor designed for topical ocular delivery to treat eye surface diseases. Used for Dry eye disease, Ocular surface inflammation.
At a glance
| Generic name | OTX-TKI |
|---|---|
| Sponsor | Ocular Therapeutix, Inc. |
| Drug class | Tyrosine kinase inhibitor |
| Target | Multiple receptor tyrosine kinases (RTKs) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
OTX-TKI is a small-molecule tyrosine kinase inhibitor formulated for direct application to the eye surface. It targets multiple receptor tyrosine kinases involved in ocular inflammation and angiogenesis, with the goal of treating dry eye disease and other anterior segment conditions through sustained local delivery.
Approved indications
- Dry eye disease
- Ocular surface inflammation
Common side effects
- Ocular irritation
- Conjunctival hyperemia
- Eye discomfort
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy (PHASE3)
- Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration (PHASE3)
- Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration (PHASE3)
- CLN-0046: Treatment of AMD Subjects With OTX-TKI (PHASE1)
- Study Evaluating the Treatment of OTX-TKI for Subjects With Neovascular Age-related Macular Degeneration (PHASE1)
- Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OTX-TKI CI brief — competitive landscape report
- OTX-TKI updates RSS · CI watch RSS
- Ocular Therapeutix, Inc. portfolio CI